Ligand acquires Vernalis at bargain price of $43M; Pfizer, Novo back $60M round for dwarfism biotech
→ Five months after a beleaguered Vernalis (LSE: $VER) decided to sell itself in the aftermath of back-to-back FDA rejections, the biotech has found a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
